Danaher Reports Third Quarter 2026 Results
Key Highlights
- ➤Revenue $6.6B, up 8.5% year-over-year
- ➤Adjusted diluted EPS $2.11, up 11.5% year-over-year
- ➤Operating cash flow $1.9B; free cash flow $1.6B
- ➤Full-year adjusted EPS guidance raised to $8.57-$8.62
- ➤Fourth-quarter core revenue growth expected at approximately 3.0%
Expert Statements
Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher Corporation
“We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets.”
Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher Corporation
“The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance.”
Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher Corporation
“Danaher has built a strong foundation, and the time I've spent with our teams and customers during my transition into the CEO role has only reinforced my conviction in the opportunities ahead.”
Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher Corporation
“Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world.”
WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
* Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year. * Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11. * Revenues increased 8.5% year-over-year to $6.6 billion. * Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year. * Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion. Julie Sawyer Montgomery, President and Chief Executive Officer, stated, "We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance."
Get started
Create a free account to read the full story.